New LEQSELVI® (deuruxolitinib) Two-Year Data in Severe Alopecia Areata Showed Sustained Efficacy and Safety at EADV Congress 2026

Sun Pharma reported up to two-year open-label extension data for FDA-approved alopecia areata drug LEQSELVI, with no deaths, thrombosis or major adverse cardiovascular events among patients receiving the 8 mg twice-daily dose. At Week 108, 93.9% of baseline responders who remained in the study maintained response, while 76.6% of baseline nonresponders had achieved response by Week 52 and 96.8% of those continuing responders maintained it through Week 108. The data support long-term efficacy and tolerability for LEQSELVI, though the product retains boxed-warning risks associated with JAK inhibitors, including serious infections, cardiovascular events, malignancy and blood clots.

Analysis

This is supportive for LEQSELVI persistence rather than a near-term demand inflection. The extension dataset is inherently enriched for tolerability and efficacy because continuation depends on remaining in study; therefore, the high maintenance rates should not be translated directly into real-world discontinuation or refill assumptions. The commercially relevant verification points over the next 1-3 months are dermatology formulary access, prior-authorization approval rates, gross-to-net discounting, and the proportion of prescriptions lost to required CYP2C9 testing or drug-interaction exclusions.

The competitive read-through is modestly favorable to Sun Pharma versus Eli Lilly (LLY, OLUMIANT) and Pfizer (PFE, LITFULO): long-duration evidence can reduce dermatologist reluctance to initiate a chronic oral JAK inhibitor. But all products remain constrained by class-wide boxed-warning perceptions, laboratory monitoring burden, and payer step edits; stronger clinical durability may primarily raise rebate competition rather than expand category economics. LLY's broader commercial infrastructure and PFE's existing dermatology relationships mean Sun must demonstrate net-new patient starts, not conference visibility, to gain share.

For 6-18 months, durable control could improve lifetime value if refill persistence offsets patient-support and monitoring costs, particularly because severe AA treatment is chronic and emotionally high-impact. The key bearish tail risk is that a low-frequency cardiovascular, thrombosis, malignancy, or serious-infection signal emerges only in broader post-marketing exposure; such an event would impair the entire oral JAK AA category and likely force heavier discounting. The disclosed safety claims are company-sponsored and insufficient to resolve that tail risk absent pharmacovigilance data and comparative real-world persistence.

There is no actionable signal in SALT: it is not an identifiable Sun Pharma equity proxy and the provided per-ticker score is neutral. For SUNPHARMA, this presentation alone is unlikely to alter consolidated estimates given the diversified base; treat any conference-driven rally as sentiment rather than an earnings catalyst until management provides prescription, revenue, or guidance data for the innovative dermatology portfolio.

Key Decisions for Investors

• No new position in SALT or a conference-driven directional position in SUNPHARMA on this release; require evidence of sequential LEQSELVI prescription growth and stable gross-to-net economics at the next results update before underwriting revenue upside.
• Place a 1-3 month competitive watch on LLY and PFE: monitor AA prescription-share data, payer coverage changes, and JAK-related safety-label or regulatory developments. A material safety event would be a negative sector read-through, with PFE potentially more exposed to risk-off sentiment given weaker earnings support.
• For an India healthcare sleeve, consider SUNPHARMA only on pullbacks after confirming innovative-medicine growth is accretive to consolidated margin rather than funded by elevated U.S. commercial spending; invalidate a constructive thesis if dermatology growth decelerates while SG&A rises faster than sales for two reporting periods.
• Avoid extrapolating extension-study response rates into valuation models. Use a conservative persistence haircut until independent real-world discontinuation, adverse-event, and payer-rejection data become available over the next 6-12 months.